Dendreon Reports Third Quarter 2007 Financi... (.dendreon.com underthe Investor/Webcas...)

Dendreon Reports Third Quarter 2007 Financial Results

Date:11/15/2007

.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 5547646. The replay will be available from 7:30 pm ET on Thursday, November 15 until 11:59 pm ET on Saturday, November 17. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, market demand for the Company's securities, pricing and other terms related to the sale of the notes, the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inhe
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007

Post Your Comments:

Dendreon Reports Third Quarter 2007 Financi...(.dendreon.com underthe Investor/Webcas...)